Targeting Hsp90 with cemdomespib reduces seizure burden and alters disease course in preclinical epilepsy models
Cemdomespib confers both acute seizure protection and long-term suppression of epileptogenesis, likely through Hsp90-dependent regulation of mitochondrial integrity and redox signaling. These findings highlight Hsp90 inhibition as a promising therapeutic strategy for seizure control while also mitigating the progression of epileptogenesis and its associated neurobehavioral impairments.
Authors
- Prince Kumar Singh (ORCID: https://orcid.org/0000-0002-6207-2435)
- Yara Sheeni (ORCID: https://orcid.org/0009-0000-4302-2128)
- Taige Zhang
- Tawfeeq Shekh‐Ahmad (ORCID: https://orcid.org/0000-0002-6165-2219)
- Aseel Saadi (ORCID: https://orcid.org/0000-0001-8899-2355)
- Rhoda Olowe Taiwo (ORCID: https://orcid.org/0000-0002-5077-0308)
- Matthew C. Walker (ORCID: https://orcid.org/0000-0002-0812-0352)
- Sereen Sandouka (ORCID: https://orcid.org/0000-0002-3499-3675)
- Alina Nemirovski
Institutions
- Hebrew University of Jerusalem (IL)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
Publication Details
- Journal
- Epilepsia
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1002/epi.70074
- Primary Topic
- Heat shock proteins research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Science and Technology, Israel
- David R. Bloom Center for Pharmacy, Hebrew University of Jerusalem